Sarcomas | Specialty

The sarcomas/tgct condition center is a comprehensive resource for clinical news and expert insights on sarcomas/tgct. Read more at OncLive.

Global Survey Outlines Optimal Population for Surgical Treatment of Proximal Femur Metastases

February 19th 2025

R. Lor Randall, MD, FACS, discusses the enrollment criteria for a trial investigating surgical outcomes in patients with proximal femur metastases.

Biomarker-Driven Research Accelerates Drug Discovery and Precision Medicine Approaches in Sarcoma

February 18th 2025

Neeta Somaiah, MD, highlights the evolving sarcoma treatment paradigm within the past 5 years, including the FDA approval of afamitresgene autoleucel.

Logistical Considerations for Delivering TCR Therapy to Patients

February 18th 2025

A panelist discusses how the logistical challenges of delivering T-cell receptor (TCR) therapy include coordinating lymphodepletion timing, managing the multiweek manufacturing process, ensuring proper handling and chain of custody of cellular products, and requiring specialized treatment centers with cell therapy expertise and infrastructure.

Comparing Postinfusion Challenges in TCR Therapy and Standard-of-Care Regimens

February 18th 2025

A panelist discusses how the postinfusion challenges with afamitresgene autoleucel (afami-cel), such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, are generally manageable and time limited compared with the chronic cumulative toxicities seen with conventional chemotherapy regimens, though careful monitoring and prompt intervention remain essential.

The OncFive: Top Oncology Articles for the Week of 2/9

February 15th 2025

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

FDA Approves Vimseltinib for Symptomatic Tenosynovial Giant Cell Tumor

February 14th 2025

The FDA has approved vimseltinib for the treatment of patients with tenosynovial giant cell tumor.

Dr Somaiah on Ongoing Research With Novel Agents in Sarcomas

February 12th 2025

Neeta Somaiah, MD, discusses ongoing research with novel agents that have emerged and those that could soon emerge in the sarcoma treatment paradigm.

Potential Impact of Afami-Cel Therapy on the Standard of Care for R/R Cases

February 11th 2025

A panelist discusses how afamitresgene autoleucel (afami-cel) therapy could potentially transform the treatment landscape for relapsed/refractory (R/R) synovial sarcoma by offering a targeted cellular therapy option with demonstrated efficacy in heavily pretreated patients, though its optimal positioning in the treatment sequence will need to be determined through additional clinical experience and data.

Approaches to First-Line Treatment for Synovial Sarcoma

February 11th 2025

A panelist discusses how the standard first-line approach for synovial sarcoma typically involves anthracycline-based chemotherapy (often doxorubicin with ifosfamide) while considering factors such as patient age, performance status, and tumor burden to determine the specific regimen intensity and duration.

Dr Livingston on the Addition of Hydroxychloroquine to Gemcitabine/Docetaxel in Osteosarcoma

February 10th 2025

John Andrew Livingston, MD, MS, discusses responses with gemcitabine, docetaxel, and hydroxychloroquine in advanced, metastatic osteosarcoma.

Diagnositc Feasibility: Liquid Biopsy vs Tissue Biopsy for Diagnostic Testing

February 4th 2025

A panelist discusses how although liquid biopsy offers potential advantages in terms of convenience and repeatability, tissue biopsy remains the current standard for MAGE-A4 testing because of the need for accurate protein expression assessment and established validation protocols, though ongoing research may eventually support complementary use of liquid biopsy approaches.

Best Practices for HLA and MAGE-A4 Testing

February 4th 2025

A panelist discusses how the main challenges in MAGE-A4 testing include optimizing the timing of both human leukocyte antigen (HLA) and MAGE-A4 expression testing, establishing standardized testing protocols across institutions, and ensuring adequate tissue availability for testing, while recommending early screening at diagnosis or first relapse to allow sufficient time for treatment planning if patients become eligible.

Routine Intraoperative Frozen Section Represents a "Very Costly" Soft Tissue Sarcoma Procedure

January 29th 2025

R. Lor Randall, MD, FACS, discusses the utility of routine intraoperative frozen section in soft tissue sarcomas and the impact of added costs.

Addressing Potential Barriers to the Adoption of Afami-Cel Therapy

January 28th 2025

A panelist discusses how key barriers to broad afamitresgene autoleucel (afami-cel) adoption include manufacturing turnaround times, the need for specialized cell therapy centers, testing requirements, and coordination of lymphodepletion timing, though these challenges are being actively addressed through improved processes and infrastructure development.

Sequencing Strategies of Afami-Cel With Chemotherapy and Targeted Therapies

January 28th 2025

A panelist discusses how afamitresgene autoleucel (afami-cel) therapy could be optimally sequenced after first- or second-line standard treatments while patients maintain good functional status, though the exact positioning would depend on individual patient factors, such as MAGE-A4 expression levels, prior therapy responses, and overall clinical condition.

Optimal Timing for Introducing Afami-Cel Therapy in the Treatment Journey

January 21st 2025

A panelist discusses how afamitresgene autoleucel (afami-cel) therapy should be considered early in the treatment journey after initial standard of care when patients still have good performance status and adequate organ function to maximize the potential benefit of this cellular therapy approach.

Key Differences in T-Cell Response Therapy vs CAR T Therapy

January 21st 2025

A panelist discusses how T-cell receptor (TCR) therapy offers potential advantages over chimeric antigen receptor (CAR) T therapy in solid tumors due to its ability to recognize intracellular antigens through human leukocyte antigen (HLA) presentation and its generally better safety profile with lower cytokine release syndrome rates, though TCR therapy faces its own challenges, including HLA restriction and potential cross-reactivity risks.

Dr Mowery on Pembrolizumab Plus Radiation Therapy and Surgery in Soft Tissue Sarcoma

January 20th 2025

Yvonne Mowery, MD, PhD, discusses the SU2C-SARC032 trial of pembrolizumab plus radiotherapy followed by surgery in soft tissue sarcoma.

Pembrolizumab/Radiation/Surgery Improves DFS in Stage III Soft Tissue Sarcoma

January 18th 2025

The addition of pembrolizumab to preoperative radiation therapy followed by surgery prolonged DFS in patients with soft tissue sarcoma of the extremity.

Early Diagnosis and Treatment Are Critical in Achieving the Best Outcomes in Sarcoma

January 16th 2025

Breelyn Wilky, MD, discusses the importance of disease screening and early diagnosis in the treatment of patients with sarcoma.